scholarly journals Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors

2020 ◽  
Vol 38 (8) ◽  
pp. 686.e1-686.e9
Author(s):  
Lorenz Haaker ◽  
Loesia Tryssesoone ◽  
Inne Renders ◽  
Annelies Verbiest ◽  
Evelyne Lerut ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Poor Prognosis ◽  
Papillary Renal Cell Carcinoma ◽  
Angiogenesis Inhibitors

scholarly journals Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Fei Meng ◽  
Luojin Zhang ◽  
Mingjun Zhang ◽  
Kaiqin Ye ◽  
Wei Guo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Kidney Cancer ◽  
Renal Cell ◽  
Poor Prognosis ◽  
Clear Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Functional Enrichment ◽  
Cancer Tissue ◽  
Down Regulation

Abstract Background BCL2L13 belongs to the BCL2 super family, with its protein product exhibits capacity of apoptosis-mediating in diversified cell lines. Previous studies have shown that BCL2L13 has functional consequence in several tumor types, including ALL and GBM, however, its function in kidney cancer remains as yet unclearly. Methods Multiple web-based portals were employed to analyze the effect of BCL2L13 in kidney cancer using the data from TCGA database. Functional enrichment analysis and hubs of BCL2L13 co-expressed genes in clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) were carried out on Cytoscape. Evaluation of BCL2L13 protein level was accomplished through immunohistochemistry on paraffin embedded renal cancer tissue sections. Western blotting and flow cytometry were implemented to further analyze the pro-apoptotic function of BCL2L13 in ccRCC cell line 786-0. Results BCL2L13 expression is significantly decreased in ccRCC and pRCC patients, however, mutations and copy number alterations are rarely observed. The poor prognosis of ccRCC that derived from down-regulated BCL2L13 is independent of patients’ gender or tumor grade. Furthermore, BCL2L13 only weakly correlates with the genes that mutated in kidney cancer or the genes that associated with inherited kidney cancer predisposing syndrome, while actively correlates with SLC25A4. As a downstream effector of BCL2L13 in its pro-apoptotic pathway, SLC25A4 is found as one of the hub genes that involved in the physiological function of BCL2L13 in kidney cancer tissues. Conclusions Down-regulation of BCL2L13 renders poor prognosis in ccRCC and pRCC. This disadvantageous factor is independent of any well-known kidney cancer related genes, so BCL2L13 can be used as an effective indicator for prognostic evaluation of renal cell carcinoma.

scholarly journals GPNMB overexpression is associated with extensive bone metastasis and poor prognosis in renal cell carcinoma

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Jian-Po Zhai ◽  
Zhen-Hua Liu ◽  
Hai-Dong Wang ◽  
Guang-Lin Huang ◽  
Li-Bo Man
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Poor Prognosis

Prognosis of renal cell carcinoma with bone metastases: Experience in 300 consecutive patients.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 463-463 ◽  
Author(s):  
Fiorella Ruatta ◽  
Lisa Derosa ◽  
Laurence Albiges ◽  
Christophe Massard ◽  
Yohann Loriot ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Poor Prognosis ◽  
Radical Resection ◽  
Initial Diagnosis ◽  
Solitary Bone Metastasis

463 Background: Bone metastases (BMs) are associated with significant morbidity and shorter survival in metastatic renal cell carcinoma (mRCC). Our purpose was to identify prognostic factors for mRCC patients (pts) with BMs. Methods: Data from mRCC pts with BMs, treated at Gustave Roussy between April 1992 and March 2016, were retrospectively collected. Age, sex, ECOG-Performance Status (PS), Memorial Sloan-Kettering Cancer Center (MSKCC) score, histology, number and site of BMs, concomitant metastases (presence and sites), therapy for BMs (radical resection or palliative surgery, radiotherapy, other local and systemic treatments), time to BMs, and outcome were analyzed. Synchronous solitary bone metastasis (SSBM) was defined as a single bone metastasis without concomitant visceral lesions at the initial diagnosis of RCC. Overall survival (OS) was calculated from the date of BMs diagnosis to death or last follow-up using Kaplan-Maier method and modelled with Cox-regression analysis. Results: Three hundred pts were identified. Median time to BMs was 32.4 months (range 0–324 months). In 64 pts (21%), bone was the only metastatic site and 22 of them (7%) had a SSBM; 236 pts (79%) had concomitant metastases in other sites. Median OS was 23.22 months. SSBM pts had better OS then those with concomitant metastases (40 vs. 20 months; p<0.001). At univariate analysis, number of BMs (p<0.0001), spinal column as site of BMs (p<0.005), concomitant metastases (p<0.0001), Fuhrman grade (p<0.001), non-clear cell histology (p<0.003), and MSKCC score (p<0.001) were significantly associated with poor prognosis. At multivariate analysis, concomitant metastases remained predictor of poor prognosis while good MSKCC, radical resection, and SSBM were predictors of better OS. Conclusions: To our knowledge,this is the largest single-institution experience evaluating prognosis in pts with BMs from RCC. This study suggests that MSKCC score, number of BMs (1 vs. >1) and radical resection are prognostic factors. Additionally, in presence of solitary bone metastasis without other concomitant metastases at the initial diagnosis of RCC, bone surgery should be considered to achieve local tumor control and increase survival.

scholarly journals Sunitinib Use for Metastatic Renal Cell Carcinoma Associated with Necrotizing Cavitary Pulmonary Aspergillosis with Aspergillus flavus: Case Report and Review of Literature

2019 ◽  
pp. 1-5
Author(s):  
Suganthini Krishnan Natesan
Keyword(s):  
Renal Cell Carcinoma ◽  
Bronchoalveolar Lavage ◽  
Cell Carcinoma ◽  
Aspergillus Flavus ◽  
Renal Cell ◽  
Poor Prognosis ◽  
Papillary Renal Cell Carcinoma ◽  
Mediastinal Lymphadenopathy ◽  
Review Of Literature ◽  
Pulmonary Aspergillosis

Sunitinib associated chronic necrotizing cavitary pulmonary aspergillosis has rarely been reported in literature. This article describes a patient with biopsy proven papillary renal cell carcinoma initially treated by radical nephrectomy. He presented about 8 months later with progressively worsening abdominal pain, headache, weight loss of 40 pounds and investigation revealed extensive retroperitoneal and mediastinal lymphadenopathy with brain metastasis. He was evaluated by oncology and started on cycles of sunitinib with dexamethasone, which he took for about 6+ months. He presented to the hospital in respiratory distress requiring intubation and ICU admission and CT scan of thorax revealed a new large consolidation with necrosis and a cavity. Given suspicion of opportunistic fungal infection with sunitinib, he was started on empiric Vancomycin, Zosyn and Voriconazole. He underwent bronchoscopy, bronchoalveolar lavage and cultures revealed Aspergillus flavus. Subsequently serum and BAL (Bronchoalveolar Lavage) galactomannan were reported positive as well. Given poor prognosis, patient’s family elected for comfort measures.

Sign in / Sign up

Export Citation Format

Share Document